Modified t cells and methods of making and using the same

Patent metadata

Field	Value
Publication number	US-2022162554-A1
Application number	US-202117525644-A
Country	US
Kind code	A1
Filing date	Nov 12, 2021
Priority date	Mar 27, 2015
Publication date	May 26, 2022
Grant date	—

Abstract

Disclosed herein are modified primary human T cells and populations thereof comprising a genome in which the CTLA4, PD1, TCRA, TCRB, and/or B2M genes have been edited to generate an off-the-shelf universal CAR T cell from allogeneic healthy donors that can be administered to any patient while reducing or eliminating the risk of immune rejection or graft versus host disease, and which are not prone to T cell inhibition, and methods for allogeneic administration of such cells to reduce the likelihood that the cells will trigger a host immune response when the cells are administered to a subject in need of such cells.

First claim

What is claimed is:

1 . A modified human T cell comprising:
(a) reduced expression of T cell receptor (TCR) alpha and/or T cell receptor (TCR) beta relative to a wild-type T cell, and (b) reduced expression of β2-microglobulin (B2M) relative to the wild-type T cell.

2 . The modified human T cell of claim 1 , wherein the gene encoding the TCR alpha on chromosome 14 has been edited so as to reduce expression of TCR alpha in the modified human T cell.

3 . The modified human T cell of claim 1 , wherein the gene encoding the TCR beta on chromosome 7 has been edited so as to reduce expression of TCR beta in the modified human T cell.

4 . The modified human T cell of claim 1 wherein the gene encoding B2M on chromosome 15 has been edited so as to reduce expression of B2M in the modified human T cell.

5 . The modified human T cell of claim 1 , comprising knock-out of the gene encoding B2M in both alleles of the genome of the modified human T cell.

6 . The modified human T cell of claim 1 , comprising reduced expression of major histocompatibility complex (MHC) class I human leukocyte antigens (HLA).

7 . The modified human T cell of claim 6 , wherein the reduced expression of MHC I HLA results from the reduced expression of B2M.

8 . The modified human T cell of claim 1 , wherein the T cell does not express one or more of TCR alpha, TCR beta, and B2M.

9 . The modified human T cell of claim 1 , wherein reduced expression of TCR alpha and/or TCR beta, and B2M results from:
contacting the modified human T cell or a progenitor cell thereof with a Cas protein or a nucleic acid encoding the Cas protein, and a single ribonucleic acid comprising a guide RNA sequence, wherein the ribonucleic acid directs the Cas protein to and hybridizes to a target motif of the respective gene encoding TCR alpha, TCR beta, or B2M, and cleaves the respective gene.

10 . The modified human T cell of claim 9 , wherein the ribonucleic acid that directs the Cas protein to and hybridizes to a target motif of the gene encoding TCR alpha comprises a polynucleotide sequence selected from the group consisting of SEQ ID NOs: 9751-9797.

11 . The modified human T cell of claim 9 , wherein the ribonucleic acid that directs the Cas protein to and hybridizes to a target motif of the gene encoding TCR beta comprises a polynucleotide sequence selected from the group consisting of SEQ ID NOs: 10533-10573.

12 . The modified human T cell of claim 9 , wherein the ribonucleic acid that directs the Cas protein to and hybridizes to a target motif of the gene encoding B2M comprises a polynucleotide sequence selected from the group consisting of SEQ ID NOs: 13258-13719.

13 . The modified human T cell of claim 9 , wherein the Cas protein is a type V Cas protein.

14 . The modified human T cell of claim 9 , wherein the expression of TCR alpha and/or TCR beta, and B2M is reduced via multiplex genomic editing.

15 . The modified human T cell of claim 1 , further comprising expression of at least one chimeric antigen receptor (CAR).

16 . The modified human T cell of claim 15 , wherein the CAR comprises: an extracellular binding domain comprising at least one single chain variable fragment (scFv), a hinge domain, a transmembrane domain, a co-stimulatory domain, and an intracellular signaling domain.

17 . The modified human T cell of claim 16 , wherein the extracellular binding domain comprises an scFv that binds to CD19, CD20, or CD22.

18 . The modified human T cell of claim 16 , wherein the extracellular binding domain comprises a first scFv that binds to CD19 and a second scFv that binds to CD22.

19 . The modified human T cell of claim 16 , wherein the hinge domain comprises a hinge domain of CD8 or CD28.

20 . The modified human T cell of claim 16 , wherein the hinge domain comprises a hinge domain of CD8.

21 . The modified human T cell of claim 16 , wherein the transmembrane domain comprises a transmembrane domain of CD8 or CD28.

22 . The modified human T cell of claim 16 , wherein the transmembrane domain comprises a transmembrane domain of CD8.

23 . The modified human T cell of claim 16 , wherein the co-stimulatory domain comprises an intracellular signaling domain of 4-1BB.

24 . The modified human T cell of claim 16 , wherein the intracellular signaling domain comprises a CD3 zeta chain.

25 . The modified human T cell of claim 15 , wherein the CAR specifically binds to an antigen or epitope of interest expressed on the surface of at least one of a damaged cell, a dysplastic cell, an infected cell, an immunogenic cell, an inflamed cell, a malignant cell, a metaplastic cell, and a mutant cell.

Assignees

• Harvard College

Inventors

• Meissner Torsten B
• Mulumba Kabungo Y
• Ferreira Leonardo M R
• Cowan Chad A

Classifications

• A61K2239/31

  characterized by the route of administration · CPC title

• A61K2039/5156

  expressing foreign proteins · CPC title

• C12N2510/00

  Genetically modified cells · CPC title

• A61P35/00

  Antineoplastic agents · CPC title

• A61P37/02

  Immunomodulators · CPC title